Avecho Biotechnology (ASX: AVE): A $45M Biotech, a Sandoz Deal & a Phase 3 Readout in Weeks — Dr Paul Gavin
Avecho Biotechnology (ASX: AVE) is heading into one of the nearest-term binary catalysts on the ASX: the interim analysis of its pivotal Phase 3 insomnia trial, due late June. In this Sharewise webinar, Wei Sim sits down with Avecho CEO Dr Paul Gavin to unpack the science, the strategy and the setup behind a ~$45M-market-cap biotech with a global pharma partner already locked in. Avecho has spent six years developing a proprietary cannabidiol (CBD) capsule enhanced with its own TPM drug-delivery technology, which increases CBD absorption roughly four-fold versus the only existing…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.